奥妥珠单抗短程输注中国专家共识(2024年版)  

Chinese expert consensus on short duration infusion of obinutuzumab(2024)

作　　者：中国抗癌协会血液肿瘤专业委员会 中华医学会血液学分会 范磊[2] 易树华 纪春岩[4] 冯茹[5] 濮益琴 郝蕊 施文瑜 朱华渊 Fan Lei;Yi Shuhua;Ji Chunyan;Feng Ru(The First Afiliated Hospital of Nanjing Medical University,Nanjing 210000,China;Hematology Hospital,Chinese Academy of Medical Sciences,Tianjin 300020,China;Qilu Hospital of Shandong University,Jinan 250000,China;Nanfang Hospital,Souhern Medical University,Guangzhou 510515.China)

机构地区：[1]不详 [2]南京医科大学第一附属医院,南京210000 [3]中国医学科学院血液病医院,天津300020 [4]山东大学齐鲁医院,济南250000 [5]南方医科大学南方医院,广州510515

出　　处：《中华血液学杂志》2024年第10期897-901,共5页Chinese Journal of Hematology

摘　　要：奥妥珠单抗自上市10余年来, 广泛应用于CD20阳性B细胞非霍奇金淋巴瘤患者并带来显著临床获益。目前国内外已有研究证实, 奥妥珠单抗90 min短程输注方案的安全性好、可行性佳。为提高患者输液的便利性和提升医疗机构输液设施的使用效率, 推荐对第1个周期奥妥珠单抗按标准速率输注未发生≥3级输液相关不良反应的患者, 后续疗程采用短程输注的方案。国内相关领域专家经过充分讨论制定本共识, 以期为临床实践提供指导。Obinutuzumab has been widely used in patients with CD20 positve B-cell non-Hodgkin's lymphoma for more than 10 years since its launch,bringing significant clinical benefits.At present,studies at home and abroad have confirmed that the 90-minute short duration infusion of obinutuzumab is safe and feasible.In order to improve the convenience of patient infusion and the efficiency of medical institutions'infusion facilities,it is recommended for patients who do not experience grade≥3 infusion-related adverse reactions in the first cycle of obinutuzumab infusion at the standard rate,a short duration infusion scheme should be used for subsequent treatment courses.This expert consensus is formulated to provide guidance forclinical practice.

关 键 词：中国专家共识 领域专家 临床实践 医疗机构 临床获益 不良反应 CD20 输注 

分 类 号：R979.1[医药卫生—药品]